ESR1 and breast carcinoma: However, a study by Hickey et al. [8] revealed a contrasting conclusion, proposing that AR exerts an inhibitory effect on the proliferation of HR–positive breast cancer and that AR agonists, rather than antagonists, are potentially effective therapeutic agents for ER–positive breast cancer.